Dynavax Technologies Corporation (DVAX) Receiving Somewhat Positive Press Coverage, Study Finds
News headlines about Dynavax Technologies Corporation (NASDAQ:DVAX) have been trending somewhat positive on Friday, Accern reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dynavax Technologies Corporation earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.0789600582057 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s analysis:
- Dynavax Technologies Corporation (DVAX): Start Paying Attention to Revised Ratings – StockNewsMagazine (stocknewsmagazine.com)
- Dynavax Technologies Corp. ($DVAX) Stock | Company Announces Positive Top Line Results for Phase 3 HEPLISAV … – Warrior Trading News (press release) (warriortradingnews.com)
- Dynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 (finance.yahoo.com)
- Critical Comparison: Sarepta Therapeutics, Inc. (SRPT) vs. Dynavax Technologies Corporation (DVAX) – StockNewsGazette (stocknewsgazette.com)
- Are Analysts Pounding the Table on Dynavax Technologies Corporation (NASDAQ:DVAX)? – Stock Press Daily (stockpressdaily.com)
Several equities research analysts recently weighed in on the stock. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Monday, July 10th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. William Blair reaffirmed an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research note on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $6.00 to $27.00 in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $23.34.
Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 17.20 on Friday. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $19.60. The company’s 50-day moving average is $13.27 and its 200 day moving average is $7.92. The stock’s market capitalization is $941.65 million.
Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.15 million. During the same period in the prior year, the company posted ($0.75) earnings per share. On average, equities analysts forecast that Dynavax Technologies Corporation will post ($1.58) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Dynavax Technologies Corporation (DVAX) Receiving Somewhat Positive Press Coverage, Study Finds” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://theolympiareport.com/2017/08/25/dynavax-technologies-corporation-dvax-receiving-somewhat-positive-press-coverage-study-finds.html.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.